| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Pharmatose DCL 14 does not have a specific biological target or receptor. As a pharmaceutical excipient, it is an inert ingredient used in drug formulations. Lactose is a sugar that can be metabolized by lactase in the body, but the DCL 14 grade is specifically designed for its physical properties as a tableting excipient rather than for any biological activity.
|
|---|---|
| ln Vitro |
In vitro, Pharmatose DCL 14 is used in pharmaceutical formulation development. It is evaluated for its physical properties such as flowability, compressibility, and compatibility with active pharmaceutical ingredients. It is not used for biological activity assays. Its primary in vitro applications are in the development and testing of solid dosage forms.
|
| ln Vivo |
In vivo, Pharmatose DCL 14 is used as an excipient in pharmaceutical formulations. It is ingested as part of the drug product and is generally considered safe. Lactose is metabolized in the body by the enzyme lactase. However, the DCL 14 grade is not used for therapeutic purposes itself but as a carrier for active pharmaceutical ingredients.
|
| Enzyme Assay |
For non-cell-based assays, Pharmatose DCL 14 is characterized using techniques such as X-ray diffraction, differential scanning calorimetry, and particle size analysis. It is not used in receptor binding assays. Its role is to serve as an excipient in pharmaceutical formulations, and its physical properties are evaluated to ensure consistent drug product quality.
|
| Cell Assay |
For in vitro cellular assays, Pharmatose DCL 14 is not typically used for cell-based functional assays. It may be used in studies of drug release and dissolution from solid dosage forms. However, its primary use is as an excipient in pharmaceutical formulation development rather than as a tool to study cell biology.
|
| Animal Protocol |
For in vivo animal studies, Pharmatose DCL 14 is not typically administered for therapeutic or pharmacological studies. It may be used as an excipient in formulations for animal studies. Its primary applications are in formulation development and as a reference standard for lactose. Comprehensive in vivo pharmacological studies are not available for this excipient.
|
| ADME/Pharmacokinetics |
Pharmatose DCL 14 is a crystalline alpha-lactose monohydrate. It is available in different grades including Pharmatose 200M and Pharmatose 450M, which differ in particle size distribution. The compound should be stored in a cool, dry place. It is for research use only and is not intended for human consumption outside of approved pharmaceutical applications.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pharmatose DCL 14 is well established as it is a commonly used pharmaceutical excipient. Lactose is generally recognized as safe. However, individuals with lactose intolerance may experience gastrointestinal discomfort. The compound is for research use only and is not intended for human consumption outside of approved pharmaceutical applications.
|
| Additional Infomation |
α-Lactose monohydrate is a glycoside.
Pharmatose DCL 14 (also known as Pharmatose 200M or Pharmatose 450M, CAS 64044-51-5) is a grade of lactose used as an excipient in pharmaceutical formulations. It is a crystalline alpha-lactose monohydrate, processed to have controlled particle size and flow properties. It is commonly used as a filler, binder, or carrier in tablets and capsules. It is available for research purposes only. |
| Molecular Formula |
C12H24O12
|
|---|---|
| Molecular Weight |
360.31
|
| Exact Mass |
360.127
|
| CAS # |
64044-51-5
|
| PubChem CID |
104938
|
| Appearance |
White to off-white solid powder
|
| Density |
1.525
|
| Boiling Point |
841.4ºC at 760 mmHg
|
| Melting Point |
433 °F (NTP, 1992)
; 201-202 °C
; Decomposes at 203.5 °C
; White powder; MP: 222.8 °C; very soluble in water; slightly soluble in ethanol; insoluble in ethyl ether, chloroform /alpha-Lactose/
|
| Flash Point |
462.7ºC
|
| Index of Refraction |
1.652
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O.O
|
| InChi Key |
WSVLPVUVIUVCRA-KPKNDVKVSA-N
|
| InChi Code |
InChI=1S/C12H22O11.H2O/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17;/h3-20H,1-2H2;1H2/t3-,4-,5+,6+,7-,8-,9-,10-,11+,12+;/m1./s1
|
| Chemical Name |
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (277.54 mM)
DMSO: 50 mg/mL (138.77 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7754 mL | 13.8769 mL | 27.7539 mL | |
| 5 mM | 0.5551 mL | 2.7754 mL | 5.5508 mL | |
| 10 mM | 0.2775 mL | 1.3877 mL | 2.7754 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06724705
Conditions:Lactose Intolerance, Adult TypeLink: https://clinicaltrials.gov/ct2/show/NCT02584439
Conditions:Healthy|Vascular Stiffness|AgingLink: https://clinicaltrials.gov/ct2/show/NCT03582176
Conditions:Elbow Fracture|Elbow Injury|Elbow Dislocation
Title:Human Cerebral Blood Flow Regulation
Status:Completed
updateDate:2025-10-03
Ctid:NCT04265053
Link: https://clinicaltrials.gov/ct2/show/NCT04265053
Conditions:Cerebral Arterial DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT06746285
Conditions:Gastrointestinal Tolerance of Probiotics in InfantsLink: https://clinicaltrials.gov/ct2/show/NCT01404754
Conditions:Psychological Effects of Study DrugLink: https://clinicaltrials.gov/ct2/show/NCT04924530
Conditions:Cardiovascular Risk Factor|Lipaemia|Metabolic DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT02999022
Conditions:FracturesLink: https://clinicaltrials.gov/ct2/show/NCT00888680
Conditions:MigraineLink: https://clinicaltrials.gov/ct2/show/NCT01041755
Conditions:Hepatic EncephalopathyLink: https://clinicaltrials.gov/ct2/show/NCT03497598
Conditions:Urinary Tract InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT01434745
Conditions:Smith-Lemli-Opitz SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT00876161
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT03878511
Conditions:Bacterial VaginosesLink: https://clinicaltrials.gov/ct2/show/NCT01550107
Conditions:SarcopeniaLink: https://clinicaltrials.gov/ct2/show/NCT02042521
Conditions:Nicotine Dependence, Cigarettes, With WithdrawalLink: https://clinicaltrials.gov/ct2/show/NCT01644877
Conditions:ParainfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT01723592
Conditions:Breast CancerLink: https://clinicaltrials.gov/ct2/show/NCT03121222
Conditions:Glutathione Metabolism AnemiasLink: https://clinicaltrials.gov/ct2/show/NCT02636413
Conditions:Lactose IntoleranceLink: https://clinicaltrials.gov/ct2/show/NCT01675986
Conditions:Feeling AnxiousLink: https://clinicaltrials.gov/ct2/show/NCT02787707
Conditions:Nausea|VomitingLink: https://clinicaltrials.gov/ct2/show/NCT02566798
Conditions:OsteoarthritisLink: https://clinicaltrials.gov/ct2/show/NCT02596360
Conditions:Experimental Pain|HyperalgesiaLink: https://clinicaltrials.gov/ct2/show/NCT02448940
Conditions:Overweight and ObesityLink: https://clinicaltrials.gov/ct2/show/NCT01848119
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT02214095
Conditions:Chronic PeriodontitisLink: https://clinicaltrials.gov/ct2/show/NCT02172508
Conditions:Pulmonary Disease, Chronic ObstructiveLink: https://clinicaltrials.gov/ct2/show/NCT00980031
Conditions:Myocardial RemodelingLink: https://clinicaltrials.gov/ct2/show/NCT01151306
Conditions:Chronic Obstructive Pulmonary DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01277237
Conditions:Non Alcoholic Fatty Liver DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT00979056
Conditions:DiarrhoeaLink: https://clinicaltrials.gov/ct2/show/NCT00624754
Conditions:Obstructive Airway DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01748279
Conditions:COPDLink: https://clinicaltrials.gov/ct2/show/NCT01812967
Conditions:Glycemic Control|Gastrointestinal Hormone Response|Healthy Young MenLink: https://clinicaltrials.gov/ct2/show/NCT01575678
Conditions:Nocturnal EnuresisLink: https://clinicaltrials.gov/ct2/show/NCT01028014
Conditions:Urethral Sphincter ActivityLink: https://clinicaltrials.gov/ct2/show/NCT00682214
Conditions:Vitamin D DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT01094925
Conditions:PainLink: https://clinicaltrials.gov/ct2/show/NCT01136317
Conditions:Gastroesophageal RefluxLink: https://clinicaltrials.gov/ct2/show/NCT01185418
Conditions:Normal VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT00983177
Conditions:Calcific TendonitisLink: https://clinicaltrials.gov/ct2/show/NCT00599859
Conditions:Lactose IntoleranceLink: https://clinicaltrials.gov/ct2/show/NCT00841230
Conditions:TinnitusLink: https://clinicaltrials.gov/ct2/show/NCT00351117
Conditions:Raynaud's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT00504946
Conditions:AsthmaLink: https://clinicaltrials.gov/ct2/show/NCT00311259
Conditions:Oxidative Stress|Inflammatory Stress|Myocardial IschaemiaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
